# Shampa Das

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3612085/publications.pdf

Version: 2024-02-01

| 34 | 1,005 | 394421 | 434195 |
|---|---|---|---|
| papers | citations | 19 | 31 |
| | | h-index | g-index |

| 34 | 34 | 34 | 1060 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance. Journal of Antimicrobial Chemotherapy, 2022, 77, 1334-1343. | 3.0 | 8 |
| 2 | Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial Resistance. Antimicrobial Agents and Chemotherapy, 2022, 66, e0218121. | 3.2 | 1 |
| 3 | Comparing probability of target attainment against Staphylococcus aureus for ceftaroline fosamil, vancomycin, daptomycin, linezolid, and ceftriaxone in complicated skin and soft tissue infection using pharmacokinetic/pharmacodynamic models. Diagnostic Microbiology and Infectious Disease, 2021, 99, 115292. | 1.8 | 15 |
| 4 | Reply to Asempa et al., â€œThe Ongoing Challenge with NDM-Harboring Enterobacteriaceae in Murine Infection Modelsâ€• Antimicrobial Agents and Chemotherapy, 2021, 65, . | 3.2 | 0 |
| 5 | Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance. Antimicrobial Agents and Chemotherapy, 2021, 65, e0029321. | 3.2 | 12 |
| 6 | Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria. Paediatric Drugs, 2021, 23, 465-484. | 3.1 | 18 |
| 7 | Selecting the dosage of ceftazidimeâ€“avibactam in the perfect storm of nosocomial pneumonia. European Journal of Clinical Pharmacology, 2020, 76, 349-361. | 1.9 | 9 |
| 8 | Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia. Antimicrobial Agents and Chemotherapy, 2020, 65, . | 3.2 | 10 |
| 9 | Pharmacodynamics of the Novel Metallo-Î²-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2020, 64, . | 3.2 | 11 |
| 10 | Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-Î²-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2020, 64, . | 3.2 | 15 |
| 11 | Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam. Antimicrobial Agents and Chemotherapy, 2020, 64, . | 3.2 | 20 |
| 12 | Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia. Antimicrobial Agents and Chemotherapy, 2019, 63, . | 3.2 | 51 |
| 13 | Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trials. International Journal of Antimicrobial Agents, 2019, 53, 830-837. | 2.5 | 5 |
| 14 | Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections. Antimicrobial Agents and Chemotherapy, 2019, 63, . | 3.2 | 34 |
| 15 | Population Pharmacokinetic Modeling and Probability of Target Attainment Analyses in Asian Patients With Communityâ€Acquired Pneumonia Treated With Ceftaroline Fosamil. Clinical Pharmacology in Drug Development, 2019, 8, 682-694. | 1.6 | 6 |
| 16 | Ceftazidimeâ€Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups. Clinical and Translational Science, 2019, 12, 151-163. | 3.1 | 65 |
| 17 | Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections. Journal of Antimicrobial Chemotherapy, 2019, 74, 425-431. | 3.0 | 31 |
| 18 | Avibactam Pharmacokinetic/Pharmacodynamic Targets. Antimicrobial Agents and Chemotherapy, 2018, 62, . | 3.2 | 62 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Population Pharmacokinetic Modelling of Ceftazidime and Avibactam in the Plasma and Epithelial Lining Fluid of Healthy Volunteers. Drugs in R and D, 2018, 18, 221-230. | 2.2 | 30 |
| 20 | Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2018, 62, . | 3.2 | 21 |
| 21 | Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4â€“5 December 2014). CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 418-429. | 2.5 | 52 |
| 22 | Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Communityâ€Acquired Bacterial Pneumonia. Journal of Clinical Pharmacology, 2017, 57, 345-355. | 2.0 | 27 |
| 23 | Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment. Journal of Clinical Pharmacology, 2017, 57, 211-218. | 2.0 | 36 |
| 24 | Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients. Antimicrobial Agents and Chemotherapy, 2016, 60, 6252-6259. | 3.2 | 44 |
| 25 | Randomized pharmacokinetic and drugâ€“drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects. Pharmacology Research and Perspectives, 2015, 3, e00172. | 2.4 | 34 |
| 26 | Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidimeâ€“avibactam in healthy Japanese volunteers. Journal of Infection and Chemotherapy, 2015, 21, 551-558. | 1.7 | 28 |
| 27 | Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. Journal of Antimicrobial Chemotherapy, 2015, 70, 2862-2869. | 3.0 | 98 |
| 28 | Randomized, placeboâ€controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidimeâ€“avibactam or ceftaroline fosamilâ€“avibactam. Journal of Clinical Pharmacology, 2014, 54, 331-340. | 2.0 | 25 |
| 29 | Determination of the safety and efficacy of therapeutic neutralization of tumor necrosis factor-Î± (TNF-Î±) using AZD9773, an anti-TNF-Î± immune Fab, in murine CLP sepsis. Inflammation Research, 2014, 63, 149-160. | 4.0 | 18 |
| 30 | Assessment of the Mass Balance Recovery and Metabolite Profile of Avibactam in Humans and In Vitro Drug-Drug Interaction Potential. Drug Metabolism and Disposition, 2014, 42, 932-942. | 3.3 | 44 |
| 31 | Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. Investigational New Drugs, 2013, 31, 370-380. | 2.6 | 59 |
| 32 | A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock. Critical Care, 2012, 16, R31. | 5.8 | 24 |
| 33 | Population pharmacokinetic/pharmacodynamic modelling of the anti-TNF-Î± polyclonal fragment antibody AZD9773 in patients with severe sepsis. Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39, 591-599. | 1.8 | 5 |
| 34 | Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Annals of Oncology, 2011, 22, 431-437. | 1.2 | 87 |